Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.37 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12016609 | 0.81 | MGLL (0.46) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL27470006 | 0.79 | FAAH (0.45) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL17181088 | 0.75 | CA12 (0.46) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL6101374 | 0.72 | QPCT (0.42) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL12964049 | 0.71 | FAAH (0.45) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL27575582 | 0.70 | FAAH (0.41) | TBXAS1FAAHMGLLCYP19A1 | |
| SCHEMBL11848834 | 0.70 | FAAH (0.47) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL19468267 | 0.70 | CYP3A4 (0.39) | TBXAS1FAAHMGLLCYP3A4CYP19A1 | |
| SCHEMBL7402246 | 0.70 | MEN1 (0.53) | TBXAS1FAAHMGLLCYP3A4CYP2D6 | |
| SCHEMBL27857452 | 0.69 | CYP3A4 (0.45) | TBXAS1FAAHMGLLCYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005739-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING A COS RELEASING COMPOUND | LUDWIG BOLTZMANN CLUSTER FUER KARDIOVASKULAERE FORSCHUNG (AT) | 2013-01-03 | — | — | US | disclosed |
| US-20130005739-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING A COS RELEASING COMPOUND | LUDWIG BOLTZMANN CLUSTER FUER KARDIOVASKULAERE FORSCHUNG (AT) | 2013-01-03 | — | — | US | disclosed |
| EP-2343063-A1 | Pharmaceutical preparations comprising a COS releasing compound | Universität Wien (AT) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011080269-A2 | PHARMACEUTICAL PREPARATIONS COMPRISING A COS RELEASING COMPOUND | Universität Wien (AT) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005739-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING A COS RELEASING COMPOUND | VIP, CRH, ADCYAP1R1 | TBXAS1 1221/4885FAAH 821/4885MGLL 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.